XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1
COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of the SARS-CoV-2 XBB.1.5 subvariant.
Perception of government performance during COVID-19 not linked to death rate.
People living in the United States are more likely to report that their government handled the COVID-19 pandemic ‘well’ than any other G7 nation despite having the highest death rate, according to a new report from the Global Listening Project.
Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults
Human infection challenge permits in-depth, early, and pre-symptomatic characterization of the immune response, enabling the identification of factors that are important for viral clearance.
WHO Information Network for Epidemics update on COVID-19
Latest information about circulation, impact and what is needed to prevent infections, severe disease, post-COVID-19 condition and deaths.
Is it bad, is it good, or is IgG4 just misunderstood?
Repeated doses of mRNA vaccines for COVID-19 result in increased proportions of anti-spike antibodies of the IgG4 subclass.
Scientific Papers
News
Article
Omicron BA.2 breakthrough infection elicits CD8+ T cell responses recognizing the spike of later Omicron subvariants
Recent studies have suggested that memory T cells play a critical role in protecting individuals immunized with SARS-CoV-2 vaccines against variants
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike
The European Respiratory Virus Surveillance Summary (ERVISS)
This interactive dashboard provides a weekly integrated epidemiological summary for influenza, RSV and severe acute respiratory syndrome coronavirus 2 for the EU/EEA and the WHO European Region
SARS-CoV-2 evolution in the Omicron era
Since SARS-CoV-2 BA.5 (Omicron) emerged and spread in 2022, Omicron lineages have markedly diversified.
The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research
In the last three years, extensive research has demonstrated the safety and efficacy of COVID-19 vaccines. These vaccines have played a critical role in reducing mortality and hospitalization rates.
Variant-adapted COVID-19 booster vaccines
Current vaccines should be tailored to combat future SARS-CoV-2 variants.
|
9th Influenza Conference 2023
The Ninth ESWI Influenza Conference: Highlights
ESWI 2023: 10 key take home messages